Lupin gets USFDA’s tentative approval for Siponimod Tablets

05 Dec 2025 Evaluate

Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Siponimod Tablets, 0.25 mg, 1 mg and 2 mg. This product would be manufactured at Lupin’s Pithampur facility in India.

Siponimod Tablets, 0.25 mg, 1 mg and 2 mg are bioequivalent to Mayzent Tablets, 0.25 mg, 1 mg and 2 mg of Novartis Pharmaceuticals Corporation, and indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults. Siponimod Tablets (RLD Mayzent) had estimated annual sales of $195 million in the U.S. (IQVIA MAT October 2025).  

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2104.50 12.55 (0.60%)
05-Dec-2025 14:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.45
Dr. Reddys Lab 1275.00
Cipla 1524.95
Zydus Lifesciences 933.45
Lupin 2104.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×